Digital Analgesic Comprising a Second-Generation Digital Health System: Increasing Effectiveness by Optimizing the Dosing and Minimizing Side Effects
Overview
Authors
Affiliations
Opioids remain an essential part of the treatment of chronic pain. However, their use and increasing rates of misuse are associated with high morbidity and mortality. The development of tolerance to opioids and analgesics further complicates dosing and the need to reduce side effects. First-generation digital systems were developed to improve analgesics but are not always capable of making clinically relevant associations and do not necessarily lead to better clinical efficacy. A lack of improved clinical outcomes makes these systems less applicable for adoption by clinicians and patients. There is a need to enhance the therapeutic regimens of opioids. In the present paper, we present the use of a digital analgesic that consists of an analgesic administered under the control of a second-generation artificial intelligence system. Second-generation systems focus on improved patient outcomes measured based on clinical response and reduced side effects in a single subject. The algorithm regulates the administration of analgesics in a personalized manner. The digital analgesic provides advantages for both users and providers. The system enables dose optimization, improving effectiveness, and minimizing side effects while increasing adherence to beneficial therapeutic regimens. The algorithm improves the clinicians' experience and assists them in managing chronic pain. The system reduces the financial burden on healthcare providers by lowering opioid-related morbidity and provides a market disruptor for pharma companies.
Inter-organ correlations in inflammation regulation: a novel biological paradigm in a murine model.
Shabat Y, Rotnemer-Golinkin D, Zolotarov L, Ilan Y J Med Life. 2025; 18(1):67-72.
PMID: 40071160 PMC: 11891616. DOI: 10.25122/jml-2024-0246.
The constrained-disorder principle defines the functions of systems in nature.
Ilan Y Front Netw Physiol. 2025; 4:1361915.
PMID: 39744508 PMC: 11688203. DOI: 10.3389/fnetp.2024.1361915.
Ilan Y Bioengineering (Basel). 2024; 11(11).
PMID: 39593770 PMC: 11592301. DOI: 10.3390/bioengineering11111111.
Ilan Y Biology (Basel). 2024; 13(10).
PMID: 39452139 PMC: 11505099. DOI: 10.3390/biology13100830.
Sigawi T, Israeli A, Ilan Y Immunotargets Ther. 2024; 13:525-539.
PMID: 39431244 PMC: 11488351. DOI: 10.2147/ITT.S477841.